Geraldine O’Sullivan Coyne

Also affiliated with Mater Misericordiae University Hospital, National Cancer Institute, National Cancer Institute, National Cancer Institute

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 36 papers. Top paper: “Atezolizumab for Advanced Alveolar Soft Part Sarcoma”.

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

New England Journal of Medicine(2023)10.1056/nejmoa2303383

N/A

3.3DataRank · unranked

158 citations

Elad Sharon, Geraldine O’Sullivan Coyne, Nancy Moore, Jared C. Foster, James Hu +26 more

Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial

Nature Medicine(2025)10.1038/s41591-024-03361-4

N/A

0.954DataRank · unranked

41 citations

Geraldine O’Sullivan Coyne, Eva Dombi, Cecilia Tibery, William G. Herrick, Staci Martin +30 more

Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study

The Lancet(2025)10.1016/s0140-6736(25)00986-9

N/A

0.707DataRank · unranked

39 citations

Geraldine O’Sullivan Coyne, Pamela L. Wolters, Staci Martin, Said Farschtschi, Ignacio Blanco +38 more

Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-20-0566

N/A

0.475DataRank · unranked

11 citations

Casey L. Kilpatrick, Melinda G. Hollingshead, Dominic Esposito, Geraldine O’Sullivan Coyne, Andrea M. Gross +7 more

Avelumab in Patients With Metastatic Colorectal Cancer

The Oncologist(2023)10.1093/oncolo/oyad162

N/A

0.332DataRank · unranked

6 citations

Geraldine O’Sullivan Coyne, Clay T. Reed, Ravi A. Madan, Julius Strauss, Seth J Steinberg +5 more

Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors

Cancer Chemotherapy and Pharmacology(2023)10.1007/s00280-023-04600-0

N/A

0.314DataRank · unranked

6 citations

Geraldine O’Sullivan Coyne, Jennifer Zlott, Shivaani Kummar, Robert Meehan, Larry Rubinstein +13 more

Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-025-04778-5

N/A

0.258DataRank · unranked

4 citations

Shivaani Kummar, Larry Rubinstein, Deborah Wilsker, Nancy Young Moore, Murielle Hogu +16 more

Posterior Subglottic Mass in a Patient With a History of Rectal Adenocarcinoma and Lung Metastases

JAMA Oncology(2020)10.1001/jamaoncol.2020.2693

N/A

0DataRank · unranked

0 citations

Geraldine O’Sullivan Coyne, Clint Allen, Craig Forrest

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0329

N/A

0DataRank · unranked

71 citations

Abdul Rafeh Naqash, Geraldine O’Sullivan Coyne, Shivaani Kummar, T. Khanh, Ashley Bruns +19 more

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2480

N/A

0DataRank · unranked

27 citations

Shivaani Kummar, James Hu, Kristen Ganjoo, Warren A. Chow, Khanh T. Do +17 more

Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial

JCO Precision Oncology(2021)10.1200/po.20.00372

N/A

0DataRank · unranked

45 citations

Shivaani Kummar, Nancy Moore, Larry Rubinstein, Yingdong Zhao, P. Mickey Williams +20 more

Advances in the management of alveolar soft part sarcoma

Current Problems in Cancer(2021)10.1016/j.currproblcancer.2021.100775

N/A

0DataRank · unranked

22 citations

Abdul Rafeh Naqash, Hari Sankaran, Alice P. Chen, Geraldine O’Sullivan Coyne

Phase 1 study of Z-Endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors

Oncotarget(2021)10.18632/oncotarget.27887

N/A

0DataRank · unranked

9 citations

Geraldine O’Sullivan Coyne, Shivaani Kummar, Jerry M. Collins, Joel M. Reid, Richard Piekarz +18 more

Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.11519

N/A

0DataRank · unranked

50 citations

Geraldine O’Sullivan Coyne, Nancy Moore, Elad Sharon, Naoko Takebe, Kristin Fino +15 more

Phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3088

N/A

0DataRank · unranked

5 citations

Geraldine O’Sullivan Coyne, Naoko Takebe, Abdul Rafeh Naqash, Jessica Mukherjee, Ashley Bruns +12 more

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2145

N/A

0DataRank · unranked

15 citations

Naoko Takebe, Shivaani Kummar, Albiruni R. Abdul Razak, Sant P. Chawla, Suzanne George +13 more

Extended progression-free survival and long-term safety of nirogacestat in patients with desmoid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11545

N/A

0DataRank · unranked

5 citations

Shivaani Kummar, Seth M. Steinberg, Murielle Hogu, Naoko Takebe, Amisha Shah +3 more

A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11528

N/A

0DataRank · unranked

3 citations

Anthony P. Conley, James Lin Chen, Elizabeth J. Davis, Melissa Burgess, Albiruni Ryan Abdul Razak +13 more

Safety, pharmacodynamic, and clinical response evaluation of nilotinib and paclitaxel in adults with refractory solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3026

N/A

0DataRank · unranked

1 citations

Geraldine O’Sullivan Coyne, Shivaani Kummar, Murielle Hogu, Larry Rubinstein, Sarah Miller +15 more

Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3022

N/A

0DataRank · unranked

2 citations

Alice P. Chen, Shivaani Kummar, Murielle Hogu, Larry Rubinstein, Naoko Takebe +15 more

Phase 2 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with granulosa cell ovarian cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5564

N/A

0DataRank · unranked

1 citations

Geraldine O’Sullivan Coyne, Jennifer Zlott, Mohamad A. Salkeni, Naoko Takebe, Ning Ma +12 more

Expanding eligibility criteria for renal and liver function in NCI-sponsored immunotherapy clinical trials.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e13610

N/A

0DataRank · unranked

1 citations

Alice P. Chen, Martha Kruhm, DAVID S. LOOSE, Geraldine O’Sullivan Coyne, Naoko Takebe +2 more

A phase 2 study of an anti–PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11533

N/A

0DataRank · unranked

1 citations

Brian Ko, Brian A. Van Tine, Anthony P. Conley, Elizabeth J. Davis, Melissa Burgess +12 more

Diagnostic performance of [68Ga]DOTATATE PET/CT, [18F]FDG PET/CT, MRI of the spine, and whole-body diagnostic CT and MRI in the detection of spinal bone metastases associated with pheochromocytoma and paraganglioma

European Radiology(2024)10.1007/s00330-024-10652-4

N/A

0DataRank · unranked

19 citations

Mayank Patel, Alexander Ling, Ritu Shah, Clara C. Chen, Corina Millo +19 more

Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-013252

N/A

0DataRank · unranked

1 citations

Geraldine O’Sullivan Coyne, Larry Rubinstein, Sarah J Shin, Naoko Takebe, Ashley Bruns +12 more

A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-025-04844-y

N/A

0DataRank · unranked

1 citations

Shivaani Kummar, Larry Rubinstein, Jennifer Zlott, Geraldine O’Sullivan Coyne, Vincent Chung +17 more

Phase 1 study of recombinant interleukin 15 in combination with nivolumab and ipilimumab in subjects with refractory cancers.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.2617

N/A

0DataRank · unranked

0 citations

Geraldine O’Sullivan Coyne, Ashley Bruns, Larry Rubinstein, Naoko Takebe, Sarah J. Shin +10 more

Phase 2 evaluation of the nilotinib-paclitaxel combination in patients with rare solid tumors: Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors trial 1 (RARE CANCER 1).

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.3015

N/A

0DataRank · unranked

0 citations

Andre DeSouza, Jared C. Foster, Naoko Takebe, Geraldine O’Sullivan Coyne, Sarah Miller +8 more

Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment

Cancer Cell(2020)10.1016/j.ccell.2020.10.015

N/A

0DataRank · unranked

104 citations

Naoko Takebe, Toshinori Hinoue, Katherine A. Hoadley, Maria Cardenas, Alina M. Hamilton +41 more

Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors (RARE CANCER) trial: RARE 2 talazoparib and temozolomide.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.3155

N/A

0DataRank · unranked

0 citations

Jennifer Zlott, Jared C. Foster, Sarah J. Shin, Geraldine O’Sullivan Coyne, Naoko Takebe +5 more

Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas

Oncotarget(2020)10.18632/oncotarget.27784

N/A

0DataRank · unranked

20 citations

Shivaani Kummar, Robert Meehan, T. Khanh, Jerry M. Collins, Larry Anderson +20 more

The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas

Neuro-Oncology Advances(2020)10.1093/noajnl/vdaa095

N/A

0DataRank · unranked

38 citations

Eva H. Baker, Andrea M. Gross, Patricia Whitcomb, Andrea Baldwin, Joanne Derdak +9 more

The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa061

N/A

0DataRank · unranked

33 citations

Lou Staudt, Naoko Takebe, David A. Wheeler, Linghua Wang, Maria Cardenas +34 more

Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology(2020)10.1007/s00280-020-04073-5

N/A

0DataRank · unranked

26 citations

Lihua Wang, Jennifer Zlott, Lamin Juwara, Joseph M. Covey, Jan H. Beumer +18 more

Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3612

N/A

0DataRank · unranked

24 citations

Andrea M. Gross, Eva Dombi, Cecilia Tibery, Amanda Carbonell, Naoko Takebe +13 more

Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3624

N/A

0DataRank · unranked

4 citations

Arjun Mittra, Geraldine O’Sullivan Coyne, Li Chen, Biswajit Das, Shivaani Kummar +15 more